Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMed

Midfacial rejuvenation by hyaluronic acid fillers and subcutaneous adipose tissue--a new concept.

Wollina U.

Laboratory Study on Facial Rejuvenation, published in Med Hypotheses (2015) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Med Hypotheses (2015)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
25665858
DOI
10.1016/j.mehy.2015.01.023

Abstract (original English)

In midface rejuvenation, hyaluronic acid (HA) fillers are commonly used as a versatile tool to improve appearance and to correct V-deformities and loss of volume. The induction of collagen as a major constituent of extracellular matrix (ECM) has been considered to be a basic effect of the rejuvenation procedure. Although commonly described as "dermal" soft fillers, histologic studies localized HA filler in the subcutaneous adipose tissue. Deep injection whenever possible lead to prolonged efficacy. Since volumizing HA filler induce mechanical stress not only to fibroblasts but adipocytes and deep injection itself causes minor trauma in the subcutaneous adipose tissue we suggest that the activation of adipose tissue-derived mesenchymal stem cells (ADMSC) is responsible for the observed clinical effects. We present a concept of filler action that discusses interactions of HA with adipocytes, ECM fiber network and ADMSC. Such a concept can explain the prolonged efficacy of deep midfacial filler placement and offers a new understanding to tailor HA fillers in the future.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Dermal FillersFaceHumansHyaluronic AcidMesenchymal Stem Cell TransplantationModels, BiologicalRejuvenationSubcutaneous Fat

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research